Is a Combination of a GnRH Agonist and Recombinant Growth Hormone an Effective Treatment to Increase the Final Adult Height of Girls with Precocious or Early Puberty?

Table 2

Characteristics of included studies of girls with early puberty.

Authors (year)	Comparison	Treatment	Duration of therapy	Subjects (n)	Before treatment					After treatment
					CA (years)	BA (years)	Height (cm)	HSDS	PAH (cm)	FAH (cm)	FAHSDS
Job et al. 1994 [11]	GH	GH 0.1 IU/kg/day, sc.	3 yr.	7 France ISS	12.2 ± 1.5	10.4 ± 0.8	131.4 ± 6.4	−2.8 ± 0.5	148.7 ± 8.3	152.8 ± 6.4	−1.1 ± 1.5
	GnRHa + GH	GH + trip 3.75 mg/28 days, i.m.		6 France ISS	12.3 ± 0.7	10.5 ± 0.7	133.3 ± 6.8	−2.8 ± 0.5	150.8 ± 9.2	154.6 ± 8.4	−1.3 ± 1.2
Saggese et al. 1995 [18]	Control	No treatment	2.0 ± 0.5 yr.	7 Italy short children	11.3 ± 0.6	11.0 ± 0.8	NA	−1.5 ± 0.7	149.0 ± 4.5	152.0 ± 3.4	−1.7 ± 0.5
	GnRHa + GH	Trip 60 μg/kg/28 days + GH 0.65 IU/kg/wk, sc.		7 Italy short children	11.5 ± 0.9	11.5 ± 0.8		−1.8 ± 0.6	146.8 ± 4.4	156.1 ± 2.1	−0.9 ± 0.3
Lanes and Gunczler 1998 [12]	Control	No treatment	2.5 yr.	10 USA ISS	11.4 ± 1.0	11.0 ± 0.8	128.9 ± 7.8	−2.3 ± 0.4	151.8 ± 10.1	150.3 ± 9.8	−2.9 ± 0.8
	GnRHa + GH	Leup 0.3 mg/kg/28 days, i.m. + GH 0.1 U/kg/day, sc.		10 USA ISS	11.8 ± 1.3	11.2 ± 0.9	128.9 ± 7.5	−2.4 ± 0.4	150.7 ± 9.8	151.7 ± 2.4	−2.7 ± 0.6
van Gool et al. 2007 [13]	Control	No treatment	3 yr.	15 Netherlands SGA/ISS	11.8 ± 0.7	NA	136.1 ± 4.5	−2.5 ± 0.5	160.0 ± 10.1	159.5 ± 5.7	−2.3 ± 0.6
	GnRHa + GH	GH 0.14 IU/kg/day, sc. + trip 3.75 mg/28 days, i.m.		17 Netherlands SGA/ISS	11.6 ± 0.7		135.4 ± 4.5	−2.4 ± 0.5	157.4 ± 8.3	161.8 ± 6.3	−2.0 ± 1.0
van der Steen et al. 2016 [27]	GH	GH 1–2 mg/m^2/day, sc.	5.9 yr.	43 Dutch SGA	7.6 ± 3.2	NA	NA	−2.3 ± 0.7	NA	NA	−1.7 ± 0.8
	GnRHa + GH	Leup 3.75 mg/kg/28 days, sc. + GH		64 Dutch SGA	7.3 ± 3.1			−2.8 ± 0.6			−1.8 ± 0.9

Trip is triptorelin. i.m. is intramuscularly. Leup is leuprolide. sc. is subcutaneous.